HCW Biologics Inc. — Form 8-K Summary
Business context and reporting period
HCW Biologics Inc. filed a Current Report on Form 8-K regarding its 2022 Annual Meeting of Stockholders held on June 15, 2022. The filing was signed on June 17, 2022. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol HCWB.
Annual meeting voting results
- Class I director elections: Scott T. Garrett and Gary M. Winer were elected to three-year terms expiring at the 2025 Annual Meeting, or until their successors are elected and qualified.
- Scott T. Garrett: 18,582,734 votes for, 347,805 withheld, and 3,567,813 broker non-votes.
- Gary M. Winer: 18,905,931 votes for, 24,608 withheld, and 3,567,813 broker non-votes.
- Independent auditor ratification: Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 22,476,600 votes for, 4,380 against, and 17,372 abstentions. Broker non-votes were not applicable.
Financial metrics and material changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other financial metrics. It does not report a material operating or financial change versus a prior comparable period.
Guidance, outlook, risks, and unusual items
The filing contains no management outlook, guidance, new risk disclosures, contingencies, or unusual financial items. The principal reported matters are the director elections and auditor ratification.
Investor verification points
- Verify the election of Scott T. Garrett and Gary M. Winer and their terms through the 2025 Annual Meeting.
- Verify the vote totals, including the 3,567,813 broker non-votes for each director nominee.
- Verify Grant Thornton LLP’s appointment for the fiscal year ending December 31, 2022.
- Review the company’s periodic financial filings separately for financial performance, liquidity, risks, and outlook, which are not addressed in this 8-K.